Cardioacc key facts
- Developer of cardiovascular interventional imaging and treatment technologies designed to better treat patients.
- It has raised $14.0M; the latest was Early Stage VC in Dec 2025.
- Notable investors include YuanBio Venture Capital, Zhehua Investment, Far East Horizon, Huaxin Capital, Ltd — 9 tracked in total.
- Status: Privately Held (backing).
- ·Watch Cardioacc: the Monday email on marks, rounds and moves
Cardioacc funding rounds
No funding rounds for Cardioacc are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Cardioacc investors
9 investors are on record for Cardioacc, including YuanBio Venture Capital, Zhehua Investment, Far East Horizon and Huaxin Capital.
About Cardioacc
Developer of cardiovascular interventional imaging and treatment technologies designed to better treat patients. The company offers interventional imaging technologies such as ICE (intracardiac echocardiography) catheter imaging and develops high-resolution surgical imaging and navigation tools, enabling patients with cardiac surgery to have safe and economic intraoperative imaging methods.
- Sector
- Healthcare
- HQ
- Shenzhen, China
- Founded
- 2021
- Employees
- 40
- Website
- cardioacc.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Cardioacc doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.